EGFR and neoplasm: A similar tumor-growth-inhibition-model-based approach has been reported for PRO95780 (anti-DR5 antibody) [70], rhuMAb VEGF (anti-VEGF antibody) [71], SI-B001 (anti-EGFR/HER3 bispecific antibody) [67], and MCLA-128 (anti-HER2/HER3 bispecific antibody).